Literature DB >> 12107856

Paroxetine associated hepatotoxicity: a report of 3 cases and a review of the literature.

T Azaz-Livshits1, A Hershko, E Ben-Chetrit.   

Abstract

We recently encountered 3 patients who had developed reversible paroxetine-associated hepatotoxicity. Two of the patients were over 80 years old and their hepatitis was accompanied by hyponatremia. In the third case, hepatitis was associated with multiple organ failure and the co-administration of trazodone. Here, we will discuss the possible role of preexisting risk factors in the development of paroxetine hepatotoxicity and review the relevant literature.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12107856     DOI: 10.1055/s-2002-31515

Source DB:  PubMed          Journal:  Pharmacopsychiatry        ISSN: 0176-3679            Impact factor:   5.788


  8 in total

1.  Antidepressant-Induced Acute Liver Injury: A Case-Control Study in an Italian Inpatient Population.

Authors:  Carmen Ferrajolo; Cristina Scavone; Monia Donati; Oscar Bortolami; Giovanna Stoppa; Domenico Motola; Alfredo Vannacci; Alessandro Mugelli; Roberto Leone; Annalisa Capuano
Journal:  Drug Saf       Date:  2018-01       Impact factor: 5.606

2.  Acute hepatitis associated with use of paroxetine.

Authors:  Maurizio Pompili; Paola Tittoto; Roberta Mascianà; Giovanni Gasbarrini; Gian Ludovico Rapaccini
Journal:  Intern Emerg Med       Date:  2008-02-12       Impact factor: 3.397

3.  Determination of antidepressants in human postmortem blood, brain tissue, and hair using gas chromatography-mass spectrometry.

Authors:  Sarah M R Wille; Els A De Letter; Michel H A Piette; Lien K Van Overschelde; Carlos H Van Peteghem; Willy E Lambert
Journal:  Int J Legal Med       Date:  2008-10-07       Impact factor: 2.686

4.  Paroxetine overdose.

Authors:  Arun K Gupta; Pankaj Verma; Samir K Praharaj; Dipayan Roy; Anuradha Singh
Journal:  Indian J Psychiatry       Date:  2005-07       Impact factor: 1.759

Review 5.  A consensus statement for safety monitoring guidelines of treatments for major depressive disorder.

Authors:  Seetal Dodd; Gin S Malhi; John Tiller; Isaac Schweitzer; Ian Hickie; Jon Paul Khoo; Darryl L Bassett; Bill Lyndon; Philip B Mitchell; Gordon Parker; Paul B Fitzgerald; Marc Udina; Ajeet Singh; Steven Moylan; Francesco Giorlando; Carolyn Doughty; Christopher G Davey; Michael Theodoros; Michael Berk
Journal:  Aust N Z J Psychiatry       Date:  2011-09       Impact factor: 5.744

6.  Schisandrin B elicits the Keap1-Nrf2 defense system via carbene reactive metabolite which is less harmful to mice liver.

Authors:  Shan Feng; Bingxun Qiu; Li Zou; Ke Liu; Xiaoyu Xu; Huifeng Zhu
Journal:  Drug Des Devel Ther       Date:  2018-11-23       Impact factor: 4.162

7.  Mixed-Etiology Restrictive Cardiomyopathy (Desminopathy and Hemochromatosis) with Complex Liver Lesions.

Authors:  Yulia Lutokhina; Olga Blagova; Alexander Panferov; Vsevolod Sedov; Evgeniya Kogan; Tatiana Nekrasova; Alexander Nedostup; Elena Zaklyazminskaya
Journal:  Genes (Basel)       Date:  2022-03-24       Impact factor: 4.141

Review 8.  Antidepressants- and antipsychotics-induced hepatotoxicity.

Authors:  Nevena Todorović Vukotić; Jelena Đorđević; Snežana Pejić; Neda Đorđević; Snežana B Pajović
Journal:  Arch Toxicol       Date:  2021-01-05       Impact factor: 5.153

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.